YouTube Facebook LinkedIn Google+ Twitter Xingrss  

Novartis Out of RNAi Research


April 15, 2014 | Novartis bows out of RNAi research, the second big pharma to do so. But does that mean RNAi is a dead end technology? Probably not. Alnylam is still heavily invested. Forbes
Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1


For reprints and/or copyright permission, please contact  Terry Manning, 781.972.1349 , tmanning@healthtech.com.